Post by Novartis India

India has built formidable strengths in scientific talent, digital capability, and pharmaceutical manufacturing. The next phase of growth, however, will depend on our ability to create an ecosystem where innovation, research, and risk-taking are rewarded. “India is important for us as a source of talent and a market where we will continue to invest. We are a pure-play pharmaceutical company, and our biggest driver is bringing innovation to patients.” — Judith Love, President, APMA International, Novartis In a conversation with The Economic Times, Judith Love reflects on the critical role India plays in Novartis’ ambition to become the leading pure-play medicines company. Reimagining medicine requires both scientific excellence and the right healthcare ecosystem. As India’s pharmaceutical landscape continues to evolve, the country offers a compelling combination of progressive policies, exceptional talent, and a growing aspiration to become a global hub for medical innovation. With a supportive and predictable regulatory environment, Novartis continues to see India as a strategic growth market, one that can help accelerate innovation and expand access to transformative medicines for patients who need them most. Read the full interview to learn more about our commitment to unlocking potential, advancing innovation, and improving and extending people’s lives. https://lnkd.in/dJdzsm82 Vikas Dandekar Rica Bhattacharyya #NovartisIndia #EconomicTimes #ReimaginingMedicine